SG11201503750YA - Process for preparing nucleoside prodrugs - Google Patents

Process for preparing nucleoside prodrugs

Info

Publication number
SG11201503750YA
SG11201503750YA SG11201503750YA SG11201503750YA SG11201503750YA SG 11201503750Y A SG11201503750Y A SG 11201503750YA SG 11201503750Y A SG11201503750Y A SG 11201503750YA SG 11201503750Y A SG11201503750Y A SG 11201503750YA SG 11201503750Y A SG11201503750Y A SG 11201503750YA
Authority
SG
Singapore
Prior art keywords
nucleoside prodrugs
preparing nucleoside
preparing
prodrugs
nucleoside
Prior art date
Application number
SG11201503750YA
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio Pertusati
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503750Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of SG11201503750YA publication Critical patent/SG11201503750YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201503750YA 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs SG11201503750YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Publications (1)

Publication Number Publication Date
SG11201503750YA true SG11201503750YA (en) 2015-06-29

Family

ID=49622844

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201503750YA SG11201503750YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG10201510324YA SG10201510324YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG10201510322UA SG10201510322UA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201510324YA SG10201510324YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
SG10201510322UA SG10201510322UA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Country Status (28)

Country Link
US (3) US10005810B2 (enExample)
EP (3) EP2920192B1 (enExample)
JP (5) JP2016506371A (enExample)
KR (1) KR20150103669A (enExample)
CN (2) CN111592577A (enExample)
AU (1) AU2013346515B2 (enExample)
CA (1) CA2891266C (enExample)
CL (1) CL2015001307A1 (enExample)
CY (2) CY1119161T1 (enExample)
DK (2) DK3235824T3 (enExample)
EA (1) EA028871B1 (enExample)
ES (3) ES2627195T3 (enExample)
HR (2) HRP20170791T1 (enExample)
HU (2) HUE033335T2 (enExample)
IL (1) IL238792A (enExample)
IN (1) IN2015DN04090A (enExample)
LT (2) LT3235824T (enExample)
MX (1) MX374779B (enExample)
MY (1) MY176133A (enExample)
NZ (1) NZ708177A (enExample)
PH (1) PH12015501090B1 (enExample)
PL (2) PL3235824T3 (enExample)
PT (2) PT3235824T (enExample)
RS (2) RS56038B1 (enExample)
SG (3) SG11201503750YA (enExample)
SI (2) SI3150616T1 (enExample)
SM (2) SMT201900341T1 (enExample)
WO (1) WO2014076490A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ES2627195T3 (es) * 2012-11-16 2017-07-27 University College Cardiff Consultants Limited Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
KR20160099090A (ko) * 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
DK3119794T3 (en) 2014-06-25 2018-01-22 NuCana plc FORMULA CONTAINING A GEMCITABIN PRODRUG
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
CN106795198B (zh) 2014-07-22 2019-09-06 努卡那公共有限公司 用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
CN106661074A (zh) * 2014-07-31 2017-05-10 桑多斯股份公司 磷酰胺的合成
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2016151542A1 (en) 2015-03-26 2016-09-29 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106478753A (zh) * 2015-09-16 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种nuc‑1031单一异构体的制备方法和用途
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
EA037248B1 (ru) * 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
WO2017098252A1 (en) 2015-12-11 2017-06-15 Nucana Biomed Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) * 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
JP2021528363A (ja) 2018-06-12 2021-10-21 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) * 2022-11-15 2024-05-23 Rome Therapeutics, Inc. Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
AU2003291726A1 (en) 2002-11-04 2004-06-07 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
CA2749394A1 (en) 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
JP5872539B2 (ja) * 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8871737B2 (en) * 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2655392B1 (en) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
HRP20160346T1 (hr) * 2011-03-01 2016-05-06 Nucana Biomed Limited Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
AU2012323937A1 (en) * 2011-10-14 2014-06-05 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
ES2627195T3 (es) * 2012-11-16 2017-07-27 University College Cardiff Consultants Limited Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato
CA2913206C (en) * 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
WO2015054465A1 (en) * 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2931804A1 (en) * 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Piperidine and piperazine derivatives and their use in treating viral infections and cancer
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
DK3119794T3 (en) 2014-06-25 2018-01-22 NuCana plc FORMULA CONTAINING A GEMCITABIN PRODRUG
CN106795198B (zh) 2014-07-22 2019-09-06 努卡那公共有限公司 用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
MX390506B (es) 2015-05-14 2025-03-20 NuCana plc Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
EA037248B1 (ru) 2015-10-05 2021-02-26 НУКАНА ПиЭлСи Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
WO2017098252A1 (en) 2015-12-11 2017-06-15 Nucana Biomed Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
AU2015418015B2 (en) 2015-12-23 2021-12-09 NuCana plc Combination therapy
ES2778933T3 (es) 2015-12-23 2020-08-12 NuCana plc Terapia de combinación
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy
JP2020171815A (ja) * 2020-07-29 2020-10-22 株式会社ユニバーサルエンターテインメント プログラム

Also Published As

Publication number Publication date
HK1210784A1 (en) 2016-05-06
US20150291650A1 (en) 2015-10-15
SI3150616T1 (sl) 2017-08-31
JP2023052536A (ja) 2023-04-11
EP2920192B1 (en) 2017-02-22
RS56038B1 (sr) 2017-09-29
US11040997B2 (en) 2021-06-22
IL238792A0 (en) 2015-06-30
JP2019196360A (ja) 2019-11-14
ES2725491T3 (es) 2019-09-24
EP3235824A1 (en) 2017-10-25
CN111592577A (zh) 2020-08-28
DK3235824T3 (da) 2019-05-20
ES2627195T3 (es) 2017-07-27
ES2618732T3 (es) 2017-06-22
HUE044605T2 (hu) 2019-11-28
EP3235824B1 (en) 2019-03-27
AU2013346515A1 (en) 2015-06-04
WO2014076490A1 (en) 2014-05-22
PT3235824T (pt) 2019-05-30
HUE033335T2 (en) 2017-11-28
EP3150616B1 (en) 2017-05-10
JP2016506371A (ja) 2016-03-03
LT3235824T (lt) 2019-07-10
KR20150103669A (ko) 2015-09-11
US20180273575A1 (en) 2018-09-27
AU2013346515B2 (en) 2017-05-25
SG10201510324YA (en) 2016-01-28
CA2891266C (en) 2020-12-08
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
EP3150616A1 (en) 2017-04-05
MY176133A (en) 2020-07-24
LT3150616T (lt) 2017-07-25
MX374779B (es) 2025-03-06
CA2891266A1 (en) 2014-05-22
PT3150616T (pt) 2017-06-09
JP2021020919A (ja) 2021-02-18
IN2015DN04090A (enExample) 2015-10-09
PH12015501090A1 (en) 2015-07-27
SMT201700349T1 (it) 2017-09-07
PL3235824T3 (pl) 2019-09-30
NZ708177A (en) 2017-08-25
RS58849B1 (sr) 2019-07-31
SG10201510322UA (en) 2016-01-28
CY1119161T1 (el) 2018-02-14
US20220033433A1 (en) 2022-02-03
US10005810B2 (en) 2018-06-26
SI3235824T1 (sl) 2019-08-30
BR112015011155A2 (pt) 2017-07-11
MX2015006195A (es) 2015-12-08
PL3150616T3 (pl) 2017-09-29
CY1121663T1 (el) 2020-07-31
EA201590955A1 (ru) 2015-08-31
SMT201900341T1 (it) 2019-07-11
JP7519259B2 (ja) 2024-07-19
CL2015001307A1 (es) 2015-12-11
EP2920192A1 (en) 2015-09-23
CN104903339A (zh) 2015-09-09
PH12015501090B1 (en) 2019-01-30
JP2018009000A (ja) 2018-01-18
DK3150616T3 (en) 2017-06-06
HRP20190831T1 (hr) 2019-08-23
HRP20170791T1 (hr) 2017-08-25

Similar Documents

Publication Publication Date Title
IL238792A0 (en) A process for the preparation of nucleoside drug derivatives
PT3333173T (pt) Métodos de preparação de análogos de nucleótidos antivirais
ZA201500603B (en) Process
GB201216921D0 (en) Process
GB201207997D0 (en) Process
GB201214326D0 (en) Process
ZA201407529B (en) Process for the preparation of 2-deoxy-2-fluro-2-methyl-d-ribofuranosyl nucleoside compounds
IL227872A0 (en) A process for the preparation of n-converted phenylhydroxylamines
GB201101370D0 (en) Process
GB201500761D0 (en) Process
GB201219224D0 (en) Process
EP2887941A4 (en) PROCESS FOR THE PREPARATION OF ANTIVIRAL COMPOUNDS
GB201318062D0 (en) Process
EP2852660A4 (en) PROCESS
ZA201502344B (en) Process
GB201103092D0 (en) Process
IL233626A (en) Process for making chloroamines
IL233388A0 (en) A process for the preparation of acetanilides
GB201317561D0 (en) Process
GB201316604D0 (en) Process
EP2831054A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF (S) -EQUOL
HUP1200614A2 (en) Process for development catalayzer
GB201223071D0 (en) Process
GB201222686D0 (en) Process
GB201220746D0 (en) Process